142 related articles for article (PubMed ID: 36385665)
21. Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non‑small cell lung cancer cells.
Kim MK; Choi MJ; Lee HM; Choi HS; Park YK; Ryu CJ
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34109989
[TBL] [Abstract][Full Text] [Related]
22. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo.
Takeda T; Tsubaki M; Genno S; Matsuda T; Yamamoto Y; Kimura A; Shimizu N; Nishida S
Clin Exp Med; 2022 May; 22(2):221-228. PubMed ID: 34196881
[TBL] [Abstract][Full Text] [Related]
24. Modulatory role of BV6 and chloroquine on the regulation of apoptosis and autophagy in non-small cell lung cancer cells.
Ali Beg MM; Saxena A; Singh VK; Akhter J; Habib H; Raisuddin S
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147964
[TBL] [Abstract][Full Text] [Related]
25. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
26. Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro.
Liu F; Shang Y; Chen SZ
Acta Pharmacol Sin; 2014 May; 35(5):645-52. PubMed ID: 24727941
[TBL] [Abstract][Full Text] [Related]
27. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
29. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
[TBL] [Abstract][Full Text] [Related]
30. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
[TBL] [Abstract][Full Text] [Related]
31. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
[TBL] [Abstract][Full Text] [Related]
32. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
Amelio I; Mancini M; Petrova V; Cairns RA; Vikhreva P; Nicolai S; Marini A; Antonov AA; Le Quesne J; Baena Acevedo JD; Dudek K; Sozzi G; Pastorino U; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10869-E10878. PubMed ID: 30381462
[TBL] [Abstract][Full Text] [Related]
33. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.
Liu J; Lin Y; Yang H; Deng Q; Chen G; He J
Tumour Biol; 2011 Dec; 32(6):1113-21. PubMed ID: 21779982
[TBL] [Abstract][Full Text] [Related]
34. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
35. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
36. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
37. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent.
Morgan MJ; Gamez G; Menke C; Hernandez A; Thorburn J; Gidan F; Staskiewicz L; Morgan S; Cummings C; Maycotte P; Thorburn A
Autophagy; 2014 Oct; 10(10):1814-26. PubMed ID: 25136801
[TBL] [Abstract][Full Text] [Related]
38. GPRC5a suppresses the proliferation of non-small cell lung cancer under wild type p53 background.
Er J; Chao L; Yiwei L; Feng X; Fei Z; Kan W; Ruifei X
Exp Lung Res; 2020 Sep; 46(7):226-233. PubMed ID: 32410473
[No Abstract] [Full Text] [Related]
39. Selective targeting p53
Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
[TBL] [Abstract][Full Text] [Related]
40. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]